Firas El Chaer, MD, MSHCM
@FirasElChaer
Followers
1K
Following
4K
Statuses
2K
Hematology & Oncology Assoc Prof @UVA | #Leukemia & #BMT | Infectious Diseases Board Certified | @Crossfit enthusiast | Tweets my own | Likes ≠ endorsement
Charlottesville, VA
Joined September 2015
RT @LeukDocJZ: Had a great time @ASCO with great friends and colleagues teaching about clinical management of AML. We even got to see ❄️! T…
0
2
0
Post-ASH 2024 MPN highlights webinar February 7, 2025
0
0
1
RT @MPN_Hub: CONGRESS | #ASH24 | PRESENTATION @FirasElChaer, @UVA, shared findings from an ongoing phase I/II trial (NCT04176198) of nuvise…
0
2
0
RT @KiarashSalafian: A great study! Honored to have contributed to it with @UvaDOM and @UVAHemeOnc and so many other institutions. #ASH24
0
4
0
RT @NicoGagelmann: Understanding and treating myelofibrosis A short thread on selected clinical abstracts from #ASH24 @ASH_hematology #mpn…
0
11
0
RT @POkhuysen: A third year fellowship position in Transplant and Oncology Infectious Diseases is open at UT MD Anderson. Cutting edge ca…
0
10
0
RT @TalhaBadarMD: #Weekend_review on #menin_inhibitors for treatment of leukemia in light on Revumenib approval (AUGMENT-101) #leusm #AML 🧵…
0
26
0
RT @GhayasIssa: Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients…
0
39
0
RT @sanamloghavi: Hot off the press… 📣 everything you wanted to know about AML #MRD Congratulations @FirasElChaer
#leusm #hemepath
0
5
0
We summarized the evidence on MRD in AML & its role in clinical practice: when & how to use it for guiding therapeutic decisions. 🙏 for my co-authors @Dr_AmerZeidan @sanamloghavi @ajperissinotti, & @DrChrisHourigan for his valuable review @LeukemiaJnl
4
31
103
RT @NicoGagelmann: Elsevier is one of the largest, most hated and most influential academic publishing companies in the world. How it sta…
0
1K
0
No matter where you are in your career, mentorship is a key to success. @DrChrisHourigan has been one of the best mentors one could ask for, and we deeply miss @page_md. She was not only a mentor and friend but also an exceptional person.
As always – these projects of ours are big team efforts - @CIBMTR @FNIH_Org @GegeGui0 @LauraWDillon @FirasElChaer and especially to our co-author, colleague, and friend Kristin Page MD (June 7, 1974–September 5, 2024) to whom all the Pre-MEASURE papers in this special issue are dedicated to.
0
0
13
RT @DrChrisHourigan: He was able to show, in a cohort of 342 adult patients with AML with FLT3-TKD in first remission undergoing allogeneic…
0
1
0
RT @DrChrisHourigan: Dr. Pranay Hegde @hegdepranay1, now at @StanfordMedRes, but HouriganLab alumni, stepped in to take this on during a @N…
0
3
0
RT @DrChrisHourigan: What about other FLT3 mutations people asked though? What about using FLT3-TKD for MRD? Variants in the FLT3 tyrosine…
0
1
0
RT @DrChrisHourigan: We followed that up in 2024 as part of our work with @FNIH_Org AML MRD Biomarkers Consortium in @JAMAOncology confirmi…
0
1
0
RT @DrChrisHourigan: In early 2023 we published the original "Pre-MEASURE" paper in @JAMA_current the largest dataset of FLT3-ITD and mutat…
0
1
0
RT @DrChrisHourigan: First article of an upcoming special issue in focusing on the “Pre-MEASURE” AML MRD project now online at https://t.co…
0
8
0
RT @ZhuoerXie: 🧬🌟💫 Introducing our CCRS Calculator!🧮 💡A simple tool to streamline consultations & support clinical…
0
8
0
RT @drsangeetmd: Check out our @MikkaelSekeres state-of-the-art comprehensive review on AML #amlsm @JAMAOnc #MedTwitter #leusm @SylvesterCa…
0
4
0